2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Radiation Therapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Hemoglobinopathies, Infectious Diseases, Viral, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5761 Kdigo acute kidney injury criteria do not predict end-stage kidney disease in newly diagnosed multiple myeloma

Sai Anoop Dhamera, BS, Krishna Chaitanya Allam, BMsc2, Ronin Joshua So Cosiquien, BS3, Hani Hassoun, MD4, Edgar Jaimes5, Abhijat Kitchlu6, Heather J. Landau, MD7, Ming Shen, BA8, Veronica Torres9, Sabine Karam, MD10
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 University of Toronto, Toronto, Ontario, Canada
7 David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 University of São Paulo, Ribeirão Preto, Brazil
10 University of Minnesota, Minneapolis, Minnesota, United States

BACKGROUND

Renal impairment occurs in approximately 20% of patients with newly diagnosed multiple myeloma (MM) and influences treatment selection and prognosis. The International Myeloma Working Group (IMWG) and Kidney Disease: Improving Global Outcomes (KDIGO) frameworks define renal impairment differently, yet their agreement and comparative ability to predict long-term renal outcomes in NDMM have not been evaluated.

METHODS

In a retrospective single-center cohort of 294 patients with NDMM, we compared two definitions of renal impairment at treatment initiation: IMWG renal impairment (IMWG-RI; serum creatinine ≥2 mg/dL or eGFR ≤40 mL/min/1.73 m²) and KDIGO acute kidney injury (KDIGO-AKI; creatinine ≥1.5× baseline). The primary endpoint was cumulative incidence of end-stage kidney disease (ESRD; eGFR <15 mL/min/1.73 m²) in a competing-risks framework with death as the competing event, modeled using age-adjusted Fine–Gray subdistribution hazard regression. Definitional agreement was assessed by Cohen's kappa. Discrimination for ESKD was compared across continuous admission eGFR, binary IMWG-RI, and binary KDIGO-AKI using area under the receiver operating characteristic curve (AUC) with DeLong testing. Renal recovery was defined as eGFR >40 mL/min/1.73 m² by end of induction. Multiple imputations (m = 20) addressed missing admission creatinine values.

RESULTS

Median age was 65 years (IQR 58–71); 62.2% were male. Induction included a proteasome inhibitor in 81.0% and an immunomodulatory drug in 77.2%. IMWG-RI was present in 49/263 evaluable patients (18.6%, 95% CI 14.4–23.8%) versus KDIGO-AKI in 9/260 (3.5%, 95% CI 1.8–6.4%). IMWG-RI prevalence varied significantly by myeloma subtype (P = 0.033), highest in light-chain (40.0%) and lowest in IgG myeloma (13.7%); high-risk cytogenetics trended toward lower IMWG-RI odds (OR 0.50, 95% CI 0.22–1.07; P = 0.061). Agreement between the two definitions was poor (κ = 0.121, 95% CI −0.104 to 0.345), with significant marginal asymmetry (McNemar P = 1.81 × 10?8). Among 44 patients classified as IMWG-RI–positive but KDIGO-AKI–negative, 93.2% had baseline eGFR <40 mL/min/1.73 m², indicating pre-existing chronic kidney disease (CKD) rather than acute injury. Patients with IMWG-RI had lower hemoglobin (9.1 vs. 11.3 g/dL; adjusted P < 0.0001), lower platelets (171.5 vs. 215.0 × 10?/L; adjusted P = 0.006), and higher beta-2-microglobulin (10.7 vs. 3.3 mg/L; adjusted P < 0.0001).

Over a median potential follow-up of 4.99 years, 16 ESRD events and 75 competing deaths occurred among 261 evaluable patients. IMWG-RI was strongly associated with ESKD (age-adjusted Fine–Gray HR 5.04, 95% CI 1.87–13.56; P = 0.0014), with 5-year cumulative incidence of 21.5% (95% CI 9.4–36.9%) versus 3.8% (95% CI 1.6–7.5%) without IMWG-RI. By contrast, KDIGO-AKI identified none of the 16 ESRD cases (sensitivity 0%, 95% CI 0.0–20.6%), compared with 50.0% for IMWG-RI (95% CI 24.7–75.3%). Continuous admission eGFR demonstrated a linear dose–response relationship with ESKD (HR 1.37 per 10 mL/min/1.73 m² decrease, 95% CI 1.19–1.59; P = 1.9 × 10?5; no nonlinearity, P = 0.410). AUC for ESKD was 0.805 (95% CI 0.702–0.908) for continuous eGFR, 0.698 (95% CI 0.578–0.818) for IMWG-RI, and 0.481 (95% CI 0.469–0.493) for KDIGO-AKI; continuous eGFR outperformed binary IMWG-RI (DeLong P = 0.015).

Renal recovery occurred in 27/49 IMWG-RI patients (55.1%); those without recovery had numerically higher ESKD rates (31.8% vs. 11.1%; P = 0.090) and mortality (40.9% vs. 22.2%; P = 0.217). The difference between involved and uninvolved free light chain concentrations (dFLC) independently predicted IMWG-RI at diagnosis (OR 1.38 per log unit, 95% CI 1.16–1.67) but did not predict renal recovery (P = 0.468). IMWG-RI was not associated with overall survival (age-adjusted HR 1.06, 95% CI 0.60–1.86; P = 0.840). Multiple imputation confirmed the primary finding (pooled HR 5.55, 95% CI 2.12–14.56; P = 0.0005).

CONCLUSIONS

In newly diagnosed MM, IMWG-RI and KDIGO-AKI show poor agreement and identify fundamentally different populations: IMWG-RI captures patients with pre-existing CKD who carry a 5-fold increased risk of ESRD, whereas KDIGO-AKI fails to identify any patient who progresses to ESRD. Continuous admission eGFR provides superior discrimination for long-term renal outcomes and should be incorporated into risk stratification at diagnosis.

Sai Anoop Dhamera, BS: No relevant conflicts of interest to declare.